SREBF2 and metabolic dysfunction-associated steatotic liver disease: This was reflected in our cohort by a decrease in enzymatic activity (arylesterase and lactonase) and disease risk, and suggests that upregulation of SREBP-2 and high PON1 activity both promote NAFLD pathogenesis.